Rockwell Medical Q2 2026: Sales Up 11%, Gross Margin Expands to 18%, Cash Flow Positive
RMTI sits 54% above its 52-week low of $4.885.
Summary
Rockwell Medical reported Q2 2026 net sales of $17.8 million, up 11% year-over-year, with gross margin expanding to 18% and positive operating cash flow. The company has sufficient liquidity for at least 12 months and remains compliant with Nasdaq listing requirements.
Key Events · Earnings and Guidance · RMTI
-
Q2 Revenue Up 11%
Net sales of $17.8 million for Q2 2026, up from $16.1 million in Q2 2025, driven by $1.3 million in sales to new Western U.S. customers.
-
Gross Margin Expands to 18%
Gross profit of $3.2 million, up 30% year-over-year, with margin improving from 16% to 18% due to lower manufacturing costs and higher volume.
-
Positive Operating Cash Flow
Net cash provided by operating activities was $1.9 million for H1 2026, a $3.6 million improvement from the prior year's $1.6 million use of cash.
-
Liquidity Runway Confirmed
$24.8 million in cash and investments as of June 30, 2026, with management stating sufficient funds for at least the next 12 months.
Analysis · RMTI · Life Sciences
Rockwell Medical's Q2 2026 results show improving fundamentals: net sales rose 11% year-over-year to $17.8 million, gross margin expanded from 16% to 18%, and operating cash flow turned positive at $1.9 million for the first half. The company has $24.8 million in cash and investments, sufficient for at least 12 months of operations. The 10-Q also reveals a $13.1 million ATM facility remains available and that CEO Mark Strobeck adopted a Rule 10b5-1 plan to sell up to 12,250 shares starting October 2026. The company regained Nasdaq compliance after its July 1 reverse split, removing a key overhang.
At the time of this filing, RMTI was trading at $7.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.6M. The 52-week trading range was $4.89 to $21.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.